Is Fannie Mae really a safe multi-bagger?

Readers who like spicier ideas by now might have heard about ongoing discussions of a potential release of two (in)famous US mortgage companies from conservatorship, i.e. a possible privatization. Yes indeed, state-owned (or partly-owned) enterprises aren’t just a thing of perceived socialist or communist countries. At the latest after none other than hedge fund billionaire Bill Ackman pitched his investment case aggressively on Twitter, stocks of Fannie Mae and Freddie Mac have made big waves. According to Ackman, there’s still a substantial upside of 5x left (after already being up by 5x since November). Is this THE no-brainer opportunity for 2025?

Continue reading

Will Altria’s stock thrive under Trump 2.0? + new research report

Although the tobacco story seems to be well-known and boring, a few things have happened in the recent past. The feared menthol ban is now off the table. And with a more corporate-friendly administration Trump 2.0, there’s a good chance tobacco companies won’t be further pressured. Marlboro-maker Altria massively outperformed the S&P 500 over the last twelve months with double (!) the latter’s return. Does Altria now belong into a well-suited stock portfolio? My Premium PLUS members receive my latest stock idea – an indirectly tobacco- / nicotine-related company with the potential to be a multi-bagger already by year-end.

Continue reading

Old money doesn’t go out of style – Ralph Lauren + new research report

Whether markets go up or down, it seems as if the spotlight only belongs to stocks linked to the sectors of tech, certain resources like uranium, lithium and maybe some oil and gas as well as the typical dividend stories. However, in the background and barely noticed by the broader public an entirely different name has made a ferocious comeback – Ralph Lauren. Boring for some, timeless for others, shares of RL outperformed the S&P 500 over the last one, three and five years (and even quarter-century). Not by little, but by a wide margin. Even before dividends. So, what’s in store for this iconic name?

Continue reading

Retail crowd’s favorite REITs: disappointment likely to continue

REITs, or real estate investment trusts, are an asset class that is typically followed and bought by investors with a focus on cash flows in the form of dividends. One of the main arguments is that this way they don’t have to bother about stock price fluctuations, as their dividend income is safe. Sounds logical, but the long-term performance of three highly celebrated such REITs is simply weak. The worst thing, I am expecting this trend to continue or even to worsen.

Continue reading

Halozyme Therapeutics – an overlooked bargain? + new stock idea

Feeling uncomfortable with everybody’s darling stocks, my motivation was and still is to find stock ideas with what I call “an own life”. With that I am looking for companies with internal triggers or catalysts which can influence shares positively (almost) regardless of what broader markets do. While I do not believe (for now) in a hefty stock market crash which pushes down all equities, I cannot rule out a nosebleed correction in the tech sector. In search of uncorrelated stock ideas, I spent some time on the Pharma / biotech sector. Halozyme Therapeutics is a seemingly lowly-valued stock. My Premium PLUS members have already received my latest potential-multi-bagger stock idea in an exclusive research report to kick off the year 2025.

Continue reading

Berkshire Hathaway – an inferior stock pick now

Risking to be accused of blasphemy with this Weekly by one or the other Buffett-fan, nonetheless I decided to have a look at the stock of Berkshire Hathaway. Warren Buffett’s investment holding has achieved a tremendous performance and beaten the markets by a wide margin since its inception. However, this was not the case in the younger past. Growth constraints are one reason. But there are quite a few other aspects that do not make this conglomerate appear to be the ultimate must-own stock.

Continue reading

Warm-up for 2025 – better expect the unexpected

Despite having done a combined review-and-outlook Weekly already, I decided to write another one with the focus solely on the outlook for 2025. Over the last weeks, I have gathered new ideas, but also brought my thoughts in order during the days that I took off. There are a few other things I wanted to share. What could the next investing year have in store for us?

Continue reading

Stocks of Dollar Stores – now finally a buy?

This Weekly is an update taking a second look at North American “dollar store” operators Dollar General and Dollarama. After almost exactly to the day two years ago, I featured both names in an analysis concluding that I have sympathies for the businesses as such, but not for their stocks. Something quite interesting has happened since: one stock totally cratered, the other advanced by another 75%. The development could not have been more different! What do both have in store now?

Continue reading

Swiss Re – next reinsurer to make a new high?

Most stocks of the world’s biggest reinsurance companies have made new all-time highs, surpassing their decades-long tops. One rare exception is the world’s number two, Swiss Re. With the painful zero interest rate period being over and despite what it looks like another rate lowering cycle, the business is benefiting in two ways: higher insurance premiums as well as higher yields on investments. Is an all-time high for the stock only a question of time?

Continue reading